Health ❯ Healthcare ❯ Patient Care ❯ Treatment Efficacy

Adverse Effects

Praxis Drug Vormatrigine Misses Primary Goal in Phase 2/3 POWER1 Trial

Praxis paused enrollment in the follow-up POWER2 study to reassess dosing and the program's next steps.

NEJM Publication Confirms Phase 3 Win for Brepocitinib in Dermatomyositis

Iza-Bren Plus Osimertinib Delivers 100% Response in Small First-Line EGFR-Mutant NSCLC Cohort